<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on February 03, 2023</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00002034</url>
  </required_header>
  <id_info>
    <org_study_id>029F</org_study_id>
    <secondary_id>ICM 1692</secondary_id>
    <nct_id>NCT00002034</nct_id>
  </id_info>
  <brief_title>A Study of the Safety and Tolerance of Long-Term Therapy With Intravenous Cytovene (Ganciclovir Sodium) for Cytomegalovirus Retinitis in Persons With AIDS</brief_title>
  <official_title>A Study of the Safety and Tolerance of Long-Term Therapy With Intravenous Cytovene (Ganciclovir Sodium) for Cytomegalovirus Retinitis in Persons With AIDS</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Hoffmann-La Roche</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>NIH AIDS Clinical Trials Information Service</source>
  <brief_summary>
    <textblock>
      To evaluate the safety and tolerance of long-term ganciclovir (DHPG) therapy for newly&#xD;
      diagnosed macular threatening Cytomegalovirus (CMV) retinitis in AIDS patients. To evaluate&#xD;
      the clinical response to a 52 week course of intravenous DHPG therapy. To evaluate the safety&#xD;
      and tolerance of long-term DHPG with concurrent treatment with zidovudine (AZT). (Patients&#xD;
      utilizing treatment with other anti-retroviral drugs will be considered for study entry on a&#xD;
      case by case basis.) To determine survival in this group of patients with AIDS and CMV&#xD;
      retinitis.&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <primary_purpose>Treatment</primary_purpose>
  </study_design_info>
  <enrollment>100</enrollment>
  <condition>Cytomegalovirus Retinitis</condition>
  <condition>HIV Infections</condition>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Zidovudine</intervention_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Ganciclovir</intervention_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria&#xD;
&#xD;
        Concurrent Medication:&#xD;
&#xD;
        Allowed:&#xD;
&#xD;
          -  Topical acyclovir.&#xD;
&#xD;
          -  Selected cytokines.&#xD;
&#xD;
          -  Allowed after the first 4 weeks of ganciclovir:&#xD;
&#xD;
          -  Zidovudine (AZT) at a reduced dose (500 mg/day) in patients who have tolerated&#xD;
             ganciclovir without grade 3/4 hematological toxicity.&#xD;
&#xD;
          -  Other anti-retrovirals after consultation with the Syntex study monitor.&#xD;
&#xD;
        Patients must have the following:&#xD;
&#xD;
          -  AIDS and newly diagnosed Cytomegalovirus (CMV) retinitis.&#xD;
&#xD;
          -  An understanding of the nature of the study, agreement to its provisions, and&#xD;
             willingness to sign the informed consent approved by the appropriate institutions&#xD;
             review board, and Syntex.&#xD;
&#xD;
        Exclusion Criteria&#xD;
&#xD;
        Co-existing Condition:&#xD;
&#xD;
        Patients with the following conditions or symptoms are excluded:&#xD;
&#xD;
          -  Have only peripheral CMV retinitis (defined as a lesion outside the major temporal&#xD;
             vascular arcades, greater than 1500 microns from the optic disk, or greater than 3000&#xD;
             microns from the fovea).&#xD;
&#xD;
          -  Ocular media opacities (corneal, lenticular, or vitreal) preventing ophthalmologic&#xD;
             retinal assessment.&#xD;
&#xD;
          -  Ocular conditions requiring immediate surgical correction (eg:&#xD;
&#xD;
          -  retinal tear or detachment).&#xD;
&#xD;
          -  Demonstrated hypersensitivity to acyclovir or ganciclovir.&#xD;
&#xD;
          -  Dementia, decreased mentation or other encephalopathic signs and symptoms which would&#xD;
             interfere with the ability of the patient to comply with the protocol.&#xD;
&#xD;
        Concurrent Medication:&#xD;
&#xD;
        Excluded:&#xD;
&#xD;
          -  Antimetabolites.&#xD;
&#xD;
          -  Alkylating agents.&#xD;
&#xD;
          -  Nucleoside analogs (excluding selected anti-retroviral agents).&#xD;
&#xD;
          -  Imipenem-cilastatin.&#xD;
&#xD;
          -  Interferons.&#xD;
&#xD;
          -  Selected cytokines.&#xD;
&#xD;
          -  Acyclovir (except topical acyclovir).&#xD;
&#xD;
        Patients with the following are excluded:&#xD;
&#xD;
          -  Have only peripheral CMV retinitis (defined as a lesion outside the major temporal&#xD;
             vascular arcades, greater than 1500 microns from the optic disk or greater than 3000&#xD;
             microns from the fovea).&#xD;
&#xD;
          -  Concomitant conditions or diseases described in Exclusion Co-Existing Conditions.&#xD;
&#xD;
        Prior Medication:&#xD;
&#xD;
        Excluded within 1 month of study entry:&#xD;
&#xD;
          -  Previous treatment with anti-cytomegalovirus therapy (e.g., ganciclovir, foscarnet or&#xD;
             CMV hyperimmune globulin).&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>13 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <location>
    <facility>
      <name>Univ of Alabama at Birmingham</name>
      <address>
        <city>Birmingham</city>
        <state>Alabama</state>
        <zip>35294</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Summitt Med Ctr / San Francisco Gen Hosp</name>
      <address>
        <city>Oakland</city>
        <state>California</state>
        <zip>94609</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Stanford at Kaiser / Kaiser Permanente Med Ctr</name>
      <address>
        <city>San Francisco</city>
        <state>California</state>
        <zip>94115</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Miami Veterans Administration Med Ctr</name>
      <address>
        <city>Miami</city>
        <state>Florida</state>
        <zip>33125</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Dr Winkler Weinberg</name>
      <address>
        <city>Roswell</city>
        <state>Georgia</state>
        <zip>30076</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>SUNY / Health Sciences Ctr at Stony Brook</name>
      <address>
        <city>Stony Brook</city>
        <state>New York</state>
        <zip>117948153</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Dr Alfred F Burnside Jr</name>
      <address>
        <city>Columbia</city>
        <state>South Carolina</state>
        <zip>29204</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Univ TX Galveston Med Branch</name>
      <address>
        <city>Galveston</city>
        <state>Texas</state>
        <zip>77550</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Southern Alberta HIV Clinic / Foothills Hosp</name>
      <address>
        <city>Calgary</city>
        <state>Alberta</state>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Canada</country>
    <country>United States</country>
  </location_countries>
  <verification_date>January 1992</verification_date>
  <study_first_submitted>November 2, 1999</study_first_submitted>
  <study_first_submitted_qc>August 30, 2001</study_first_submitted_qc>
  <study_first_posted type="Estimate">August 31, 2001</study_first_posted>
  <last_update_submitted>June 23, 2005</last_update_submitted>
  <last_update_submitted_qc>June 23, 2005</last_update_submitted_qc>
  <last_update_posted type="Estimate">June 24, 2005</last_update_posted>
  <keyword>Retinitis</keyword>
  <keyword>AIDS-Related Opportunistic Infections</keyword>
  <keyword>Ganciclovir</keyword>
  <keyword>Drug Interactions</keyword>
  <keyword>Cytomegalovirus Infections</keyword>
  <keyword>Acquired Immunodeficiency Syndrome</keyword>
  <keyword>Zidovudine</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Infections</mesh_term>
    <mesh_term>Cytomegalovirus Retinitis</mesh_term>
    <mesh_term>Retinitis</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Zidovudine</mesh_term>
    <mesh_term>Ganciclovir</mesh_term>
    <mesh_term>Ganciclovir triphosphate</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

